Shareholders approve reincorporation to Nevada and name change to Channel Therapeutics; board adds $500k to buyback

Pelthos Therapeutics Inc.

Proposal 4 approved: reincorporation from Delaware to Nevada and renaming to Channel Therapeutics Corp. (2.6M for, 2.3K against, 929.7K abstain).
Board authorizes amendment to repurchase plan: adds $500k (total $750k) and extends termination to June 30, 2025.
Proposal 1: all five director nominees elected (Todd Davis, Ezra Friedberg, Francis Knuettel II, Dr. Richard Malamut, Chia-Lin Simmons).
Proposal 2: amendment to 2023 Equity Incentive Plan increasing authorized shares approved (3.5M for).
Proposal 5: Marcum LLP ratified as independent auditor for FY2024 (3.9M for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.